🇺🇸 Pegylated interferon alfa 2b in United States

88 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Fatigue — 14 reports (15.91%)
  2. Influenza Like Illness — 14 reports (15.91%)
  3. Anaemia — 10 reports (11.36%)
  4. Diarrhoea — 9 reports (10.23%)
  5. Nausea — 9 reports (10.23%)
  6. Dyspnoea — 7 reports (7.95%)
  7. Malaise — 7 reports (7.95%)
  8. Headache — 6 reports (6.82%)
  9. Hyperparathyroidism — 6 reports (6.82%)
  10. Vomiting — 6 reports (6.82%)

Source database →

Pegylated interferon alfa 2b in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is Pegylated interferon alfa 2b approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for Pegylated interferon alfa 2b in United States?

Kirby Institute is the originator. The local marketing authorisation holder may differ — check the official source linked above.